Increased blood-based intratumor heterogeneity (bITH) is associated with unfavorable outcomes of immune checkpoint inhibitors plus chemotherapy in non-small cell lung cancerJuan Zhou, Chunxia Su, Jing Zhao et al.|BMC Medicine|2022Cited by 21
Harnessing local and system immune profiling delineating differential responders to first-line sintilimab (anti-PD-1 antibody) combined with chemotherapy in extensive-stage small cell lung cancer: an exploratory biomarker analysis of a phase II studyMengqing Xie, Chunxia Su, Minwei Bao et al.|Signal Transduction and Targeted Therapy|2025Cited by 6
Additional file 1 of Increased blood-based intratumor heterogeneity (bITH) is associated with unfavorable outcomes of immune checkpoint inhibitors plus chemotherapy in non-small cell lung cancerJuan Zhou, Chunxia Su, Ying Huang et al.|Open MIND|2022Cited by 0